Journal
DIAGNOSTICS
Volume 13, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/diagnostics13020272
Keywords
theranostics; nanomedicine; immunotherapy; breast cancer
Categories
Ask authors/readers for more resources
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Current treatment options are limited and variable response to chemotherapy exists due to disease heterogeneity. This review discusses FDA-approved targeted therapies for TNBC, as well as novel theranostic approaches using nanocarriers. These approaches aim to improve diagnosis and treatment of TNBC by enabling targeted drug delivery and visualization of the lesion.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis. Current endocrine therapy or anti HER-2 therapy is not available for these patients. Chemotherapeutic treatment response varies among patients due to the disease heterogeneity. To overcome these challenges, theranostics for treating TNBC have been widely investigated. Anticancer material conjugated nanoparticles with target-binding ligand and tracer agents enable simultaneous drug delivery and visualization of the lesion with minimal off-target toxicity. In this review, we summarize recently FDA-approved targeted therapies for TNBC, such as poly-ADP-ribose polymerase (PARP) inhibitors, check point inhibitors, and antibody-drug conjugates. Particularly, novel theranostic approaches including lipid-based, polymer-based, and carbon-based nanocarriers are discussed, which can provide basic overview of nano-therapeutic modalities in TNBC diagnosis and treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available